Drugs / Anfibatide
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT04404790 | Sep 2020 → Mar 2021 | — | Lee's Pharmaceutical Limited | Suspended | No outcome recorded |
| Phase 1 | NCT01588132 | Sep 2010 → Mar 2011 | blood coagulation disease, coronary artery disorder | Lee's Pharmaceutical Limited | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04021173 | Jul 2019 → Jul 2021 | acquired thrombotic thrombocytopenic purpura | Lee's Pharmaceutical Limited | Unknown | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 1/2 | NCT01585259 Comparator | Jul 2012 → Dec 2014 | myocardial infarction | Lee's Pharmaceutical Limited | Completed | No outcome recorded |
| Phase 2 | NCT02495012 Comparator | Aug 2015 → Mar 2016 | ST-elevation myocardial infarction | Lee's Pharmaceutical Limited | Unknown | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Anfibatide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04021173 ↗ |
| Known as | Agkisacucetin | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297694 ↗ |
| Action | Inhibit | “This study shows that intravenous administration of the platelet receptor GP Ib antagonist anfibatide is feasible and safe to inhibit platelet aggregation without increasing...” PMID 34478577 ↗ Sep 20211“Platelet glycoprotein Ib alpha chain antagonist” CHEMBL4297694 ↗ |
| Modality | Protein / enzyme biologic | — CHEMBL4297694 ↗ |
| Route | Intravenous | “intravenous administration of the platelet receptor GP Ib antagonist anfibatide” PMID 34478577 ↗ Sep 2021 |
| Target | GP1BA | “Platelet glycoprotein Ib alpha chain antagonist” CHEMBL4297694 ↗ |